dermatomyositis

Brepocitinib, a novel oral TYK2/JAK1 inhibitor, demonstrated significant clinical efficacy in the phase 3 VALOR trial for dermatomyositis, achieving superior improvement scores, higher remission rates and meaningful reductions in corticosteroid use compared with placebo. Rapid improvements in itch, muscle strength and quality of life were observed, with a favorable safety profile and no increase in major adverse events such as thrombosis or malignancy. These findings mark a major advancement in targeted therapy for this difficult-to-treat autoimmune disease.

The phase 3 VALOR trial shows that brepocitinib significantly improves skin disease, muscle strength, and functional disability in adults with dermatomyositis. As the first modern targeted therapy to demonstrate positive results, brepocitinib may transform treatment options while reducing steroid reliance.